Shenzhen Weiguang Biological Products Co., Ltd.

SZSE:002880 Stock Report

Market Cap: CN¥6.4b

Shenzhen Weiguang Biological Products Past Earnings Performance

Past criteria checks 5/6

Shenzhen Weiguang Biological Products has been growing earnings at an average annual rate of 4.2%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 5.2% per year. Shenzhen Weiguang Biological Products's return on equity is 11.4%, and it has net margins of 21.4%.

Key information

4.2%

Earnings growth rate

4.2%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate5.2%
Return on equity11.4%
Net Margin21.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shenzhen Weiguang Biological Products makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:002880 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,16725013251
30 Jun 241,11422712966
31 Mar 241,06622013165
31 Dec 231,04921912464
30 Sep 2399219610958
30 Jun 2389317210440
31 Mar 237391389136
01 Jan 236681189036
30 Sep 227021418341
30 Jun 228031828842
31 Mar 229072048949
01 Jan 229072059048
30 Sep 219142078951
30 Jun 218331838047
31 Mar 218541868349
31 Dec 209051908045
30 Sep 208951839146
30 Jun 208681789143
31 Mar 208421768235
31 Dec 198211718140
30 Sep 197531586627
30 Jun 197491586630
31 Mar 197261597029
31 Dec 186881577124
30 Sep 186511567526
30 Jun 186101486034
31 Mar 186061456331
31 Dec 176231556526
30 Sep 175741446518
30 Jun 17592154800
31 Mar 17577154960
31 Dec 16566153780
30 Jun 16513132680
31 Mar 16501125480
31 Dec 15501125650
31 Dec 14453101550
31 Dec 1335589590

Quality Earnings: 002880 has high quality earnings.

Growing Profit Margin: 002880's current net profit margins (21.4%) are higher than last year (19.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002880's earnings have grown by 4.2% per year over the past 5 years.

Accelerating Growth: 002880's earnings growth over the past year (27.6%) exceeds its 5-year average (4.2% per year).

Earnings vs Industry: 002880 earnings growth over the past year (27.6%) exceeded the Biotechs industry 1.3%.


Return on Equity

High ROE: 002880's Return on Equity (11.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 12:03
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenzhen Weiguang Biological Products Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai WangCitic Securities Co., Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.